Because of its risk of recurrence compared to SST, a steroid cell tumor NOS must be ruled out using FOXL2 and TFE3 immunomarkers, which are usually expressed in SST and not expressed in steroid cell tumors NOS [14,62]. This evidence concerns the gene FOXL2 and neoplasm.